Ra Medical appoints CEO as interim CFO; gets FDA clearance but won't sell DABRA 2.0

Catheter Precision, Inc.

Jonathan Will McGuire, current CEO, appointed interim CFO effective July 8, 2022; no extra compensation.
FDA 510(k) clearance granted for DABRA 2.0 catheter on July 5, 2022.
Company states it has no plans to commercialize the DABRA 2.0 catheter.
Board continues strategic alternatives review; in June 2022 cut workforce by ~65% to preserve capital.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Jonathan Will McGuire

interim Chief Financial Officer

VTAK · Catheter Precision, Inc.

Effective: 2022-07-08
Filed: July 8, 2022, 7:59 PM ET

On July 8, 2022, the board of directors of the Company appointed Jonathan Will McGuire to act as interim Chief Financial Officer effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Will McGuire was appointed as interim Chief Financial Officer at Catheter Precision, Inc..

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

On July 8, 2022, the board of directors of the Company appointed Jonathan Will McGuire to act as interim Chief Financial Officer effective immediately.

View on SEC.gov

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-025521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.